following an abbreviated submission:
linzagolix (Yselty®) is accepted for use within NHSScotland.
Indication under review: in adult women of reproductive age for symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis.
Linzagolix offers an additional treatment choice in the therapeutic class of gonadotrophin-releasing hormone (GnRH) receptor antagonists that is taken with concomitant hormonal add-back therapy (ABT).
Linzagolix has the advantage of allowing flexibility in the choice of concomitant ABT compared with an alternative GnRH antagonist that is available with ABT as a fixed-dose combination therapy. Linzagolix with ABT is more expensive than the alternative but the overall net budget impact is likely to be small.
Download detailed advice244KB (PDF)
Medicine details
- Medicine name:
- linzagolix (Yselty)
- SMC ID:
- SMC2841
- Indication:
In adult women of reproductive age for symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis.
- Pharmaceutical company
- Theramex UK LTD
- BNF chapter
- Obstetrics, gynaecology, and urinary-tract disorders
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 13 October 2025